Relay Therapeutics (RLAY) Cash from Investing Activities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Cash from Investing Activities data on file, last reported at $32.9 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $32.9 million, down 22.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $183.2 million (up 2102.79% YoY), and the FY2025 annual result was $192.8 million, up 569.29% from the prior year.
• Cash from Investing Activities fell to $32.9 million in Q1 2026 per RLAY's latest filing, from $35.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $75.3 million in Q1 2023 and troughed at -$146.9 million in Q4 2022.
• A 5-year average of $14.9 million and a median of $39.7 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities plunged 276.78% in 2024, then jumped 303.24% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$146.9 million in 2022, then soared by 140.61% to $59.7 million in 2023, then tumbled by 51.41% to $29.0 million in 2024, then grew by 22.29% to $35.5 million in 2025, then decreased by 7.22% to $32.9 million in 2026.
• Business Quant data shows RLAY's Cash from Investing Activities at $32.9 million in Q1 2026, $35.5 million in Q4 2025, and $39.7 million in Q3 2025.